E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Neuroprotective Agents to Treat Dementias"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 December 2019

Special Issue Editor

Guest Editor
Prof. Dr. Simona Rapposelli

Department of Pharmacy, University of Pisa, Via Bonanno, 6, 56126 Pisa, Italy
Website | E-Mail
Interests: drug discovery; synthesis and structure–activity relationships of biologically active compounds; multitarget agents; hybrid compounds; kinase inhibitors; pro-autophagic molecules; neuroprotective agents; antioxidant molecules; medicinal chemistry

Special Issue Information

Dear Colleagues,

Alzheimer’s disease (AD) is a progressive age-dependent and multi-factorial neurodegenerative pathology that leads to cognitive dysfunction and continues to have a significant impact on society as a whole. Given that the main drawback of AD therapy remains to be its limited effectiveness, the search for new potential drugs is heavily pursued. Several pathways are involved in AD’s etio-pathology, both in peripheral and central human districts that include aberrant lipid metabolism, oxidative stress, mitochondrial impairment, neuroinflammatory processes, impairment of autophagic flux, and blood–brain barrier (BBB) disruption.

This Special Issue “Neuroprotective Agents to Treat Dementias” welcomes the submission of review and research articles related to the design and synthesis of new molecules that could provide an innovative approach for the treatment of AD or other forms of dementia, including mechanisms and pharmacological characterization. Moreover, full research articles and/or reviews covering drugs repurposing approaches in neurodegenerative diseases are welcome.

Prof. Dr. Simona Rapposelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autophagy inducers
  • antioxidant agents
  • neuroinflammation
  • dementia
  • anti-ageing agents
  • multitarget drugs
  • GSK3
  • metabolic disorders
  • sirtuin
  • NrF2-ARE pathway
  • oxidative stress
  • mitochondrial dysfunction
  • metal chelating agents
  • Alzheimer’s disease
  • Repurposing drugs

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle
Preparation of Benzothiazolyl-Decorated Nanoliposomes
Molecules 2019, 24(8), 1540; https://doi.org/10.3390/molecules24081540
Received: 16 March 2019 / Revised: 14 April 2019 / Accepted: 17 April 2019 / Published: 18 April 2019
PDF Full-text (3161 KB) | HTML Full-text | XML Full-text
Abstract
Amyloid β (Aβ) species are considered as potential targets for the development of diagnostics/therapeutics towards Alzheimer’s disease (AD). Nanoliposomes which are decorated with molecules having high affinity for Aβ species may be considered as potential carriers for AD theragnostics. Herein, benzothiazolyl (BTH) decorated [...] Read more.
Amyloid β (Aβ) species are considered as potential targets for the development of diagnostics/therapeutics towards Alzheimer’s disease (AD). Nanoliposomes which are decorated with molecules having high affinity for Aβ species may be considered as potential carriers for AD theragnostics. Herein, benzothiazolyl (BTH) decorated nanoliposomes were prepared for the first time, after synthesis of a lipidic BTH derivative (lipid-BTH). The synthetic pathway included acylation of bis(2-aminophenyl) disulfide with palmitic acid or palmitoyl chloride and subsequent reduction of the oxidized dithiol derivative. The liberated thiols were able to cyclize to the corresponding benzothiazolyl derivatives only after acidification of the reaction mixture. Each step of the procedure was monitored by HPLC analysis in order to identify all the important parameters for the formation of the BTH-group. Finally, the optimal methodology was identified, and was applied for the synthesis of the lipid-BTH derivative. BTH-decorated nanoliposomes were then prepared and characterized for physicochemical properties (size distribution, surface charge, physical stability, and membrane integrity during incubation in presence of buffer and plasma proteins). Pegylated BTH-nanoliposomes were demonstrated to have high integrity in the presence of proteins (in comparison to non-peglated ones) justifying their further exploitation as potential theragnostic systems for AD. Full article
(This article belongs to the Special Issue Neuroprotective Agents to Treat Dementias)
Figures

Graphical abstract

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top